Skip Navigation



ToxSci Advance Access published online on October 15, 2008

Toxicological Sciences, doi:10.1093/toxsci/kfn218
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
107/1/298    most recent
kfn218v2
kfn218v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sevil, K.
Right arrow Articles by Jean-Louis, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sevil, K.
Right arrow Articles by Jean-Louis, F.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

An increased regional blood flow precedes mesenteric inflammation in rats treated by a phosphodiesterase 4 inhibitor

Korkmaz Sevil*,{dagger}, Maupoil Véronique*, Sobry Cécile{dagger}, Brunet Chloé*, Chevalier Stephan{dagger} and Freslon Jean-Louis*

* Université François-Rabelais de Tours, CNRS FRE 3092, 31 Avenue Monge, F-37200 Tours, France {dagger} Drug Safety R&D, Pfizer, Z.I. Pocé-sur-Cisse, BP 159, F-37401, Amboise, France

Corresponding author: JL FRESLON Université François-Rabelais de Tours, CNRS FRE 3092, 31 Avenue Monge, F-37200 Tours, France, Phone: +33 2 47 36 72 02, Fax: +33 2 47 36 72 07. E-mail address: jean-louis.freslon{at}univ-tours.fr.

Received July 25, 2008; revision received October 5, 2008; accepted October 7, 2008


   Abstract

The study was undertaken to assess the hemodynamic effects induced by a single dose of the phosphodiesterase 4 inhibitor CI-1044, which is known to cause mesenteric vascular alterations in rats. In the present study, an administration of 160 mg/kg of CI-1044 caused perivascular and interstitial inflammation, with infiltrates of admixed neutrophils and macrophages but without evidence of vascular necrosis (ileum, 15/20 rats; duodenum + jejunum, 7/20 rats). 4h after administration, blood pressure was decreased (-13 %). A fluorescent microspheres technique demonstrated that, in these conditions, cardiac output was doubled (+100 %) and total peripheral resistance was decreased (-54 %). The largest increases in blood flow were measured in the duodenum (+101 %), in the jejunum (+110 %) and in the ileum (+192 %). Therefore, the mesentery was the most sensitive organ affected by the drug and, within this area, parts with the highest incidence of vascular alteration were those which had shown the highest increase in flow. In addition, isolated precontracted mesenteric resistance arteries dissected from untreated animals were fully relaxed when incubated with increasing concentrations of CI-1044 up to 2.5 x10-5 M. At this latter concentration, contractile abilities and sensitivities to the physiological agonist noradrenaline and to the thromboxane analogue U46619 [GenBank] were significantly attenuated (-28 and -27 % respectively). This effect could lead to a decreased response to noradrenaline and possibly to other agonists in vivo consistent with the vasodilation observed with the microsphere technique.. These data provide evidence that the PDE4 inhibitor CI-1044 induces changes of vascular tone that could lead to histological alterations in the mesenteric area.

Key Words: drug-induced vascular injury; mesenteric artery; PDE4 inhibitor; mesenteric blood flow; vasoreactivity.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.